Abstract
Forty patients with advanced breast cancer, randomised to receive CMF or weekly low dose Epirubicin, were evaluated by UICC criteria of response and WHO toxicity criteria, in addition to three QoL instruments: the 'Qualitator' daily diary card, 4 weekly Nottingham Health Profile (NHP) and Linear Analogue Self-Assessment (LASA). Response rates were 58% for CMF and 29% for epirubicin (chi 2 = 3.51, 1 d.f., P > 0.05). Median time to treatment failure was 24 weeks for CMF, 7 weeks for epirubicin (P < 0.05) but survival was similar in both groups. Survival was better for responders than for non-responders (medians 87 and 30 weeks, P = 0.02). CMF caused more objective alopecia (P < 0.001), nausea and vomiting (P < 0.001) and haematological toxicity (P < 0.02). However, QoL measures only recorded a significant difference in energy and pain, influenced primarily by the non-responders in each treatment group but with no difference in overall global scores. Scores for responders, irrespective of treatment, were better to start with (LASA P = 0.001); at 12 weeks, scores had improved (Qualitator P < 0.05; NHP P < 0.05). Scores in non-responders showed no change. In this small study aggressive chemotherapy gave better response and similar survival without impairing Quality of life overall. Detailed QoL measurement should be integral to all cancer chemotherapy trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fraser, S., Dobbs, H., Ebbs, S. et al. Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Br J Cancer 67, 402–406 (1993). https://doi.org/10.1038/bjc.1993.74
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.74
This article is cited by
-
Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007
Journal of Experimental & Clinical Cancer Research (2008)
-
Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value?
Breast Cancer Research and Treatment (2004)
-
Evaluation of quality of life for diverse patient populations
Breast Cancer Research and Treatment (1996)
-
MRC quality of life studies using a daily diary card—practical lessons learned from cancer trials
Quality of Life Research (1995)
-
Quality of life bibliography and indexes: 1993 update
Quality of Life Research (1995)